Zachery Reichert
University of Michigan Rogel Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Zachery Reichert as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04748042 · Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)University of Michigan Rogel Cancer Center · active not recruiting · Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease · principal investigator
- Ph2NCT03787680 · Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)University of Michigan Rogel Cancer Center · active not recruiting · Prostate Cancer · principal investigator
- Ph2NCT03556904 · FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)University of Michigan Rogel Cancer Center · completed · Prostate Cancer · principal investigator
- Ph2NCT03287050 · Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial CarcinomaUniversity of Michigan Rogel Cancer Center · terminated · Urothelial Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:21 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.N Engl J Med · 2025147 citationsRCR 31.0
- Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.JAMA Oncol · 202091 citationsRCR 3.7
- 74 citationsRCR 16.6
- Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).Clin Cancer Res · 202448 citationsRCR 5.1
- Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.Clin Cancer Res · 202437 citationsRCR 3.8
- A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigue.Cell Rep Med · 202511 citationsRCR 3.8
- Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.JAMA Netw Open · 20218 citationsRCR 0.3
- Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.Clin Genitourin Cancer · 20207 citationsRCR 0.2
- A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.Int J Radiat Oncol Biol Phys · 20235 citationsRCR 0.4
- A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.J Urol · 20234 citationsRCR 0.3